Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE studyHagop M. Kantarjian, Anjali S. Advani, Tao Wang et al.|Cancer|2019Cited by 327
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Hagop Kantarjian, Nicola Gökbuget et al.|Leukemia Research|2019Cited by 52
Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.Elias Jabbour, Hagop M. Kantarjian, Nicola Gökbuget et al.|Journal of Clinical Oncology|2018Cited by 6
Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trialAttaya Suvannasankha, Alexander M. Lesokhin, Jonathan L. Kaufman et al.|Blood|2025Cited by 6